Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1999-08-02
2000-12-26
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514573, 514913, A61K 31215, A61K 3119
Patent
active
061660736
ABSTRACT:
Compositions containing DP-agonist and FP-agonists prostaglandin agonists and methods of their use in treating glaucoma or ocular hypertension are disclosed.
REFERENCES:
patent: 4029681 (1977-06-01), Smith
patent: 4097489 (1978-06-01), Bundy
patent: 4288616 (1981-09-01), Sih
patent: 4599353 (1986-07-01), Bito
patent: 5173507 (1992-12-01), DeSantis et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5321128 (1994-06-01), Stjernschantz et al.
patent: 5565492 (1996-10-01), DeSantis et al.
Alm, Effects of Topically Applied PGF.sub.2.alpha. and Its Isopropylester On Normal and Glaucomatous Human Eyes, Progress in Clinical Biological Research, Alan R. Liss, Inc., pp. 447-458 (1989).
Alm, The potential of prostaglandin derivates in glaucoma therapy, Current Opinion in Ophthalmology, vol. 4, No. 11, pp. 44-50 (1993).
Barraclough, Synthesis and Platelet Aggregation Inhibiting Activity of Acid Side-chain Modified Hydantoin Prostaglandin Analogues, Archives in Pharmacology, vol. 326, No. 2, pp. 85-95 (1993).
Brubaker, Fluorophotometric Studies of Prostaglandin Effects On the Human Eye: The Lack of Association of Reduced Intraocular Pressure with Altered Flow of Barrier Function, Progress in Clinical and Biological Research, vol. 393, Alan R. Liss, Inc., pp. 477-481 (1989).
Bundy, Synthesis and Platelet Aggregation Inhibiting Activity of Prostaglandin D Analogues, Journal of Medicinal Chemistry, vol. 26, pp. 790-799 (1983).
Crawford, Effects of topical PGF.sub.2.alpha. on aqueous humor dynamics in cynomolgus monkeys, Current Eye Research, vol. 6, No. 8, pp. 1035-1044 (1987).
Das, 9,11-Epoxy-9-homoprosta-5-enoic Acid Analogues as Thromboxane A.sub.2 Receptor Antagonists, Journal of Medicinal Chemistry, vol. 33, No. 6, pp. 1741-1748 (1990).
Giles et al., A comparative study of the prostanoid receptor of 9.alpha.11.beta.-prostaglandin F.sub.2 and prostaglandin D.sub.2, British Journal Pharmacol., vol. 104, pp. 541-549 (1991).
Giuffre, The Effects of Prostaglandin F.sub.2.alpha. the Human Eye, Graefe's Archieve Ophthalmology, vol. 222, pp. 139-141 (1985).
Goh, Effect of topical prostaglandin D.sub.2 on the aqueous humor dynamics in rabbits, Graefe's Archive Clin. Exp. Ophthalmology, vol. 227, pp. 476-481 (1989).
Goh, Effects of Prostaglandin D.sub.2 and Its Analogues on Intraocular Pressure in Rabbits, Jpn J. Opthalmol., vol. 32, pp. 471-480 (1988).
Kerstetter, Prostaglandin F.sub.2.alpha. -1-Isopropylester Lowers Intraocular Pressure Without Decreasing Aqueous Humor Flow, American Journal of Opthalmology, vol. 105, pp. 30-34 (1988).
Krauss et al., Prostanoid FP-receptor mediated contractions of the cat iris sphincter depend on calcium influx, FASEB J, vol. 5, No. 4, p. A476 (1991), abstract 609.
Lake, Cloning of the rat and human prostaglandin F.sub.2.alpha. receptors and the expression of the rat prostaglindin F.sub.2.alpha. receptor, FEBS Letters 355, pp. 317-325 (1994).
Nakajima, Effects of Prostaglandin D.sub.2 and its analogue, BW245C, on Intraocular Pressure in Humans, Graefe's Archive Opthalmology, vol. 229, pp. 411-413 (1991).
Sharif, N.A., Williams, G.W. and DeSantis, L.M. Neurochemistry Research, vol. 20, pp. 669-674 (1994).
Sharif, N.A., Xu, S. and Yanni, J.M. Journal of Ocular Pharmacology, vol. 10, pp. 653-664 (1994).
Thierauch, Prostaglandins and their Receptors: II. Receptor Structure and Signal Transduction, Journal of Hypertension, vol. 12, pp. 1-5 (1994).
UF-021, Drugs of the Future, 17(3), pp. 193-196 (1992).
Veldhuis, Prostaglandin F.sub.2.alpha. Initiates Polyphosphatidylinositol Hydrolysis and Membrane Translocation of Protein Kinase C In Swine Ovarian Cells, Biochemical and Biophysical Research Communications, vol. 149, No. 1, pp. 112-117 (1987).
Woodward, Ca.sup.2+ Transients Evoked By Prostanoids in Swiss 3T3 Cells Suggest an FP-Receptor Mediated Response, Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 21, edited by B. Sameulsson et al., Raven Press, Ltd., New York, pp. 367-370 (1990).
Dean Thomas R.
Hellberg Mark
Sallee Verney L.
Alcon Laboratories Inc.
Fay Zohreh
Mayo Michael C.
LandOfFree
Combinations of DP and FP type prostaglandins for lowering IOP does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations of DP and FP type prostaglandins for lowering IOP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of DP and FP type prostaglandins for lowering IOP will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-995453